mutated allele. In the case of a mutation, the PCR generates an additional 203 bp PCR product. 1 The second strategy consists of nested PCR, and subsequent restriction enzyme digestion with BsaXI (New England Biolabs, Hitchin, UK). In case of mutated DNA, the PCR product remains undigested, whereas unmutated DNA results in two fragments of 170 and 203 bp in size. 4 None of the MDS/AML cases showed evidence of the JAK2 V617F mutation, regardless of the presence or absence of fibrosis. Interestingly, the mutation was detected in three of four cases (75%) diagnosed as MDS/MPD. In contrast to the MDS/AML with fibrosis, these four patients showed some clinical features of chronic myeloproliferative disease, including splenomegaly, leukocytosis and/or thrombocytosis, as well as, morphological features of CMPD in the trephine biopsy. One of the positive cases was classified as atypical chronic myelogenous leukemia negative for BCR/ABL fusion transcripts.
Bcl2 was identified as the cellular oncogene product associated with the t(14,18) translocation commonly seen in B-cell lymphomas and is the founding member of a family of proteins that regulate apoptosis. 1 Bcl2 protects cells from a wide range of stress challenges and thus high Bcl2 levels would be predicted to favor chemoresistance.
1,2 However, Bcl2 expression levels alone do not always correlate with poor prognosis (e.g. some acute myeloid leukemias (AML) patient subsets, pediatric acute lymphoblastic leukemia patients).
2 As Bcl2 expression alone cannot explain its full and potent antiapoptotic activity, other regulatory mechanisms must be involved.
The phosphorylation status of Bcl2 influences its function. [3] [4] [5] [6] Growth agonist-induced phosphorylation of Bcl2 at serine 70 is required for Bcl2's full and potent antiapoptotic function. [4] [5] [6] PKC a and extracellular signal-related kinase (ERK) have been identified as Bcl2 kinases that promote survival. 5, 6 In hematopoietic cell lines, overexpression of exogenous kinase or treatment of cells with kinase agonist (i.e. bryostatin for PKC a and aurintricarboxylic acid for ERK) results in enhanced Bcl2 phosphorylation and increased resistance to apoptosis on induction of stress challenges (i.e. IL-3 withdrawal or treatment of cells with chemotherapeutic agents). [5] [6] [7] Consequently, the phosphorylation status of Bcl2 in AML blast cells or any other human malignancy is unknown. Furthermore, the consequence of phosphorylated Bcl2 on the survival of AML blast cells has yet to be determined. In the present study, we investigate Bcl2 phosphorylation status using metabolic radiolabeling and activation status of PKC a and ERK in blast cells from AML patients and examine their effect on patient survival. We find that Bcl2 is phosphorylated in nearly half the AML blast cells tested. Furthermore, Bcl2 is always phosphorylated in AML blast cells with activated PKC a and ERK but never in cells that lack both activated kinases. Finally, AML patients with blast cells expressing phosphorylated Bcl2 exhibit shorter overall survival (particularly when PKC a was active) compared to patients with blast cells expressing unphosphorylated Bcl2. This finding is consistent with our previous study that determined that expression levels of proteins (i.e. Bax and PKC a) that affect the functional status of Bcl2 modify the prognostic impact of Bcl2. 8 Commercially available phospho-Bcl2 antibodies have significant crossreactivity with nonphosphorylated Bcl2 protein and thus are not specific enough for analysis of Bcl2 phosphorylation status (data not shown). In studies on AML cell lines, we used metabolic radio-labeling to examine Bcl2 phosphorylation. 5 In the present study, we utilized this assay to determine Bcl2 phosphorylation status in primary blast cells derived from bone marrow of 15 AML patients. Bone marrow or peripheral blood was obtained for in vitro studies from patients with newly diagnosed or recurrent AML with high (450%) blast count. Informed consent was obtained following institutional guidelines. Clinical data for AML patients are presented in Table 1 . Mononuclear cells were separated by Ficoll-Hypaque density-gradient centrifugation. Samples were processed within 30 min after they were obtained. Cells (20-40 Â 10 6 ) were labeled with [ 32 P]orthophosphoric acid for 2 h and Bcl2 was immunoprecipitated using an antibody that was previously described. 5 OCI-AML3 cells (kind gift of Dr Mark Minden, Ontario Cancer Institute, Toronto, ON, Canada) were used as a positive control for Bcl2 phosphorylation and were included in each experimental set.
In one case (patient 12), we were able to perform experiments on both bone marrow and peripheral blood from a single patient. As shown in Table 1 , Bcl2 is phosphorylated in approximately half of AML blast cells studied (i.e. seven of 15). A representative set is shown in Figure 1a . Bcl2 is phosphorylated in samples 10, 11, and 12 but not sample 8. These findings represent the first identification of phosphorylated Bcl2 in primary AML blast cells. With Bcl2 phosphorylation confirmed as a physiologic phenomenon, we next investigated which Bcl2 kinases might be involved.
PKC a and ERK expression and phosphorylation were examined by Western analysis in 13 of the 15 AML patient samples (samples 9 and 12 are not included due to limited number of isolated cells). Activation of ERK and PKC a varied (Table 1; Figure 1b) . As presented in Table 1 , four of 13 samples were devoid of active kinase, two of 13 samples displayed active ERK alone, four of 13 samples displayed active PKC a alone, and three of 13 samples displayed both active PKC a and ERK. Every phospho-Bcl2 positive sample exhibited phosphorylated ERK and/or PKC a (Table 1) . Protein kinase profiles from representative samples 8, 10, and 11 are shown in Figure 1b . Bcl2 was not phosphorylated in sample 8. Interestingly, neither 
Figure 1
Bcl-2 phosphorylation, extracellular signal-related kinase (ERK) and PKC a phosphorylation status in primary acute myeloid leukemias (AML) samples. (a) Representative group of samples (number 8, 10, 11, and 12) from the same experimental set show the result of metabolic 32 P-labeling of immunoprecipitated Bcl-2. For samples 8, 10, 11, and 12, bone marrow (BM) was isolated. AML blast cells were extracted and incubated with the isotope for 2 h. Peripheral blood (PB) from patient 12 was similarly treated. Cells then were lysed and Bcl2 immunoprecipitated, and phosphorylation determined as previously described. 5 (b) Blast cells were lysed and protein extracts were separated by Sodium dodecyl sulphate-polyacrylamide gel electrophoresis; Western blot analysis was performed with antibodies against phospho-ERK (Cell Signaling, Beverly, MA, USA), ERK (Cell Signaling), Bcl2 (Dako, Carpenteria, CA, USA), phospho-PKC a (Cell Signaling), PKC a (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and GAPDH (Chemicon International, Temecula, CA, USA). A representative group of samples is shown.
Letters to the Editor ERK nor PKC a were phosphorylated in this sample (Table 1 ; Figure 1b ). Sample 10 represents an example where Bcl2 is phosphorylated but only one kinase is active (i.e. PKC a). Sample 11 represents the set of samples where both ERK and PKC a were active (Table 1; Figure 1a ). While some samples that lacked phosphorylated Bcl2 exhibited active PKC a (i.e. samples 6 and 7) or active ERK (i.e. sample 4), Bcl2 was phosphorylated in all cases where both kinases are active (i.e. samples 5, 11, and 15; Table 1 ). The relationship between kinase activation and Bcl-2 was found to be statistically significant (P ¼ 0.046) using Pagano and Halvorsen's variation of Fisher's Exact Test. 9 As shown in Table 2 , all samples with no active Bcl2 kinase displayed unphosphorylated Bcl2. Conversely, Bcl2 was phosphorylated in all samples where both Bcl2 kinases were activated (Table 2) . This finding suggests a close relationship exists between activation of PKC a and ERK and Bcl2 phosphorylation status in AML blast cells.
For sample 12 both bone marrow and peripheral blood were analyzed (Figure 1a) . Interestingly, Bcl2 phosphorylation levels were greater in bone marrow derived blast cells compared to blasts in peripheral blood. While this observation is for a single patient, it is tempting to speculate that perhaps Bcl2 phosphorylation status in blast cells might be affected by interactions with cells in the bone marrow stroma. Experiments to address this question are ongoing.
We next evaluated the effect of phospho-Bcl-2, phospho-PKC a, phospho-ERK and their combination on median survival. Frequency counts for the number of deaths, proportions and median survival estimates, hazard ratios and 95% confidence intervals (CI) are reported for all potential risk factors and pairwise combinations of risk factors in Table 3 . The time to death or censoring was computed in days since treatment for each patient. Survival was censored at the date of the last follow-up if death was not observed. Survival probabilities were estimated nonparametrically using Kaplan-Meier's product limit method. Cox proportional hazards regression models were used to model survival as a function of each potential risk factor after adjusting for the patient being new or having undergone treatment previously. All statistical analyses were performed using SAS 9.1 (SAS Institute Inc., Cary, NC, USA). Acute myeloid leukemias patients whose blasts express phosphorylated Bcl-2 may have shorter overall survival (N ¼ 7; 79 days) compared to patients with no phosphorylated Bcl-2 (N ¼ 8; 197.5 days), although this difference is not statistically significant (hazard ratio ¼ 3.783; 95% CI, 0.93-15.4; P ¼ 0.0628). Survival of AML patients with active PKC a was shorter compared to patients with no phosphorylated PKC (hazard ratio ¼ 4.363; 95% CI, 0.96-19.8; P ¼ 0.0561). Extracellular signal-related kinase activation was not prognostic (P ¼ 0.1723). Patients expressing both, active PKC a and phosphorylated Bcl2 have shorter overall survival compared to patients with no active PKC a and unphosphorylated Bcl2 (hazard ratio ¼ 7.995; 95% CI, 1.00-63.76; P ¼ 0.0497). This finding supports a role for PKC a in prosurvival Bcl2 phosphorylation. 5, 8 Previously, we determined that PKC a modulates the ability of Bcl2 to serve as a prognostic factor in AML. 8 However, in that study PKC a phosphorylation of Bcl2 was implied as no direct analysis of Bcl2 phosphorylation was performed. The current data supports the ability of PKC a to 
